Biomedical Occupation or Discipline
Moderna to Cut 10% of Workforce in $1.5B Cost-Saving Push
Moderna; layoffs; workforce reduction; cost-cutting; $1.5 billion savings; 2025; Stéphane Bancel; biotechnology; COVID-19 vaccine
Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital
Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company
GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China’s Hengrui Pharma
GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal
Roche Doubles Down on Alzheimer’s with Next-Gen Amyloid-Lowering Drug Trontinemab
Roche; Alzheimer’s disease; trontinemab; amyloid-lowering drug; Brainshuttle; Phase III trial; TRONTIER studies; drug development; biomarkers; early intervention
Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal
Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships
Biogen Pledges $2 Billion Manufacturing Investment in North Carolina
Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion
Viatris Ophthalmic Drug Fails Phase 3 for Blepharitis; Company Weighs Next Steps
Viatris; ophthalmic drug; Phase 3 study; blepharitis; MR-139; clinical trial failure; drug development; pimecrolimus; pipeline; strategic review
Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal
Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments
Pfizer Warns of ‘Near-Term Stock Out’ of Penicillin Used for Treating Syphilis in Pregnant Women After Recall
Pfizer; penicillin recall; Bicillin L-A; syphilis treatment; pregnant women; drug shortage; congenital syphilis; FDA; Extencilline; public health
AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup
AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development